{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:44:23Z","timestamp":1790628263048,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eprac.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:54:08Z","timestamp":1707411248000},"page":"470-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values"],"prefix":"10.1016","volume":"30","author":[{"given":"Terry J.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Cockerham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Barretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9570-2280","authenticated-orcid":false,"given":"Alex","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Enstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Brandolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.eprac.2024.02.002_bib1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2024.02.002_bib2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2024.02.002_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.eprac.2022.06.003","article-title":"Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in patients in the United States","volume":"28","author":"Wang","year":"2022","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2024.02.002_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","article-title":"Quality of life in a German graves orbitopathy population","volume":"152","author":"Ponto","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.eprac.2024.02.002_bib5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","article-title":"Psychosocial morbidity of Graves' orbitopathy","volume":"63","author":"Kahaly","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2024.02.002_bib6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.eprac.2024.02.002_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"Wiersinga","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2024.02.002_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","article-title":"Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL","volume":"82","author":"Terwee","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.eprac.2024.02.002_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2024.02.002_bib10","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.eprac.2024.02.002_bib11","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.02.002_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaophthalmol.2022.3225","article-title":"Utility assessment of moderate to severe thyroid eye disease health states","volume":"141","author":"Smith","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.eprac.2024.02.002_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/bjo.85.3.327","article-title":"Utility values associated with blindness in an adult population","volume":"85","author":"Brown","year":"2001","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.eprac.2024.02.002_bib14","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1002\/edm2.357","article-title":"Thyroid disease-specific quality of life questionnaires \u2013 a systematic review","volume":"5","author":"Uslar","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"issue":"6","key":"10.1016\/j.eprac.2024.02.002_bib15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2024.02.002_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.eprac.2024.02.002_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","article-title":"EuroQol protocols for time trade-off valuation of health outcomes","volume":"34","author":"Oppe","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.eprac.2024.02.002_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1467-842X.2001.tb00294.x","article-title":"How can I deal with missing data in my study?","volume":"25","author":"Bennett","year":"2001","journal-title":"Aust N Z J Public Health"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:48:26Z","timestamp":1722890906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1530891X24000648"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.02.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}